These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 25360712)

  • 21. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
    Jellinger PS
    Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular mechanisms by which GLP-1 RA and DPP-4i induce insulin sensitivity.
    Yaribeygi H; Sathyapalan T; Sahebkar A
    Life Sci; 2019 Oct; 234():116776. PubMed ID: 31425698
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes.
    van Genugten RE; Möller-Goede DL; van Raalte DH; Diamant M
    Diabetes Obes Metab; 2013 Jul; 15(7):593-606. PubMed ID: 23216746
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus.
    Siddiqui NI
    Mymensingh Med J; 2009 Jan; 18(1):113-24. PubMed ID: 19182763
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiovascular Effects of Incretin-Based Therapies.
    White WB; Baker WL
    Annu Rev Med; 2016; 67():245-60. PubMed ID: 26768240
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recent advances in incretin-based therapies.
    Russell-Jones D; Gough S
    Clin Endocrinol (Oxf); 2012 Oct; 77(4):489-99. PubMed ID: 22804841
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel Therapeutic Approaches in Diabetes.
    Gallwitz B
    Endocr Dev; 2016; 31():43-56. PubMed ID: 26824365
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Q: Do incretin drugs for type 2 diabetes increase the risk of acute pancreatitis?
    Olansky L
    Cleve Clin J Med; 2010 Aug; 77(8):503-5. PubMed ID: 20682512
    [No Abstract]   [Full Text] [Related]  

  • 29. [New therapies for type 2 diabetes: what place for incretin-based agents and rimonabant compared to the previous ones?].
    Halimi S; Debaty I; Villaret L; Muller M
    Rev Med Interne; 2008 Nov; 29(11):881-90. PubMed ID: 18722695
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incretin-based therapies for type 2 diabetes mellitus: effects on insulin resistance.
    Grigoropoulou P; Eleftheriadou I; Zoupas C; Diamanti-Kandarakis E; Tentolouris N
    Curr Diabetes Rev; 2013 Sep; 9(5):412-7. PubMed ID: 23855508
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
    Vergès B; Bonnard C; Renard E
    Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emerging incretin based therapies for type 2 diabetes: incretin mimetics and DPP-4 inhibitors.
    Stonehouse A; Okerson T; Kendall D; Maggs D
    Curr Diabetes Rev; 2008 May; 4(2):101-9. PubMed ID: 18473757
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incretin-based therapy of type 2 diabetes mellitus.
    Knop FK; Vilsbøll T; Holst JJ
    Curr Protein Pept Sci; 2009 Feb; 10(1):46-55. PubMed ID: 19275672
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Update on incretin hormones.
    Phillips LK; Prins JB
    Ann N Y Acad Sci; 2011 Dec; 1243():E55-74. PubMed ID: 22545749
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
    Drucker DJ; Nauck MA
    Lancet; 2006 Nov; 368(9548):1696-705. PubMed ID: 17098089
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.
    Pratley RE; Salsali A
    Curr Med Res Opin; 2007 Apr; 23(4):919-31. PubMed ID: 17407649
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glucose-Dependent Insulinotropic Peptide Stimulates Glucagon-Like Peptide 1 Production by Pancreatic Islets via Interleukin 6, Produced by α Cells.
    Timper K; Dalmas E; Dror E; Rütti S; Thienel C; Sauter NS; Bouzakri K; Bédat B; Pattou F; Kerr-Conte J; Böni-Schnetzler M; Donath MY
    Gastroenterology; 2016 Jul; 151(1):165-79. PubMed ID: 26971825
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination therapies of DPP4 inhibitors and GLP1 analogues with insulin in type 2 diabetic patients: a systematic review.
    Rizos EC; Ntzani EE; Papanas N; Tsimihodimos V; Mitrogianni Z; Maltezos E; Elisaf MS
    Curr Vasc Pharmacol; 2013 Nov; 11(6):992-1000. PubMed ID: 22724475
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1.
    Duffy NA; Green BD; Irwin N; Gault VA; McKillop AM; O'Harte FP; Flatt PR
    Eur J Pharmacol; 2007 Jul; 568(1-3):278-86. PubMed ID: 17573070
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glucagon-Like Peptide-1 Formulation--the Present and Future Development in Diabetes Treatment.
    Lee CY
    Basic Clin Pharmacol Toxicol; 2016 Mar; 118(3):173-80. PubMed ID: 26551045
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.